AzTrials
AzTrials

Paediatric SurgeryPhase 4SAPSOS2NCT05681871

South African Paediatric Surgical Outcomes Study 2

A Phase 4 study testing Ferrous gluconate syrup or ferrous fumarate/folic acid tablets in people with Paediatric Surgery and Anaemia, run by University of Cape Town at 2 sites in South Africa.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Preoperative anaemia has been shown to be associated with worse outcomes after surgery in both adults and children. Limited research has been done on how common preoperative iron-deficiency anaemia (IDA) is in children and how best to treat it. Oral iron is a relatively cost-effective treatment for IDA. Read more about this study

Who is it for?
Ages 6 months to 16 years
What is being tested?
Ferrous gluconate syrup or ferrous fumarate/folic acid tablets
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
755 participants
Where
2 sitesSouth Africa
Study dates
9 Feb 2023to 31 May 2025
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 months to 16 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Age > 6 months to <16 years
  • Noncardiac surgery
  • Elective surgery
  • Anaemic as per World Health Organisation criteria

Who cannot join

  • Patient or parent refusal
  • Unable to obtain written consent at the surgical outpatient clinic
  • Surgery planned within 4 weeks from surgical outpatient visit
  • Known history of acquired iron overload, family history of haemochromatosis or thalassemia
  • Known reason for anaemia (e.g., untreated vitamin B12 or folate deficiency or haemoglobinopathy)
  • Treatment with oral iron, erythropoietin, IV iron therapy or blood transfusion in the previous 12 weeks
Show all 9Show fewer
  • Known hypersensitivity to oral iron or other contraindication to oral iron
  • Temperature > 38.0 °C or receiving non-prophylactic antibiotics
  • Acute liver failure

Trial locations and contacts

2 sites in 1 country.

South Africa2 sites
  • Tygerberg Hospital

    Cape Town, Western Cape, 7505

  • Red Cross War Memorial Children's Hospital

    Cape Town, Western Cape, 7700

Other trials in South Africa

About this study

Official title: A South African Multi-centre Pilot Trial to Assess the Feasibility and Clinical Efficacy of Preoperative Oral Iron to Treat Preoperative Iron-deficiency Anaemia in Children Undergoing Elective Noncardiac Surgery

Preoperative anaemia has been shown to be associated with worse outcomes after surgery in both adults and children. Limited research has been done on how common preoperative iron-deficiency anaemia (IDA) is in children and how best to treat it. Oral iron is a relatively cost-effective treatment for IDA. This study aims to show whether giving children with IDA oral iron for 6-12 weeks before their surgery significantly improves their haemoglobin.

Read the detailed description

Studies in both paediatric and adult patients have shown an association between preoperative anaemia and increased postoperative morbidity and mortality, and transfusion rates. The incidence of preoperative anaemia in the secondary analysis of the SAPSOS cohort of children who underwent noncardiac surgery was 46.2%. IDA has been shown to represent up to 30% of preoperative anaemia in adults. Iron deficiency and IDA are of even greater concern in children, because of the negative impact it may have on cognitive performance.

A recent Cochrane review on the role of preoperative iron in reducing perioperative blood transfusion in adult patients found no significant reduction in the administration of allogeneic blood transfusion in patients who had received preoperative iron compared with those who did not. These findings were supported by the Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT) trial which found no difference in blood transfusion or death between the patients who did and did not receive intravenous iron. However, these findings have generated much discussion in the literature and concerns have been raised about the clinical application of this study. The mean haemoglobin (Hb) difference between the two groups post intervention (0.47g.dl-1) highlights the need for greater understanding of the impact of an intervention on the absolute or relative increase in Hb when designing trials looking at the impact of iron treatment on perioperative outcomes. Dosing regimens of preoperative oral iron varies widely between studies further complicating the ability to draw conclusions of the role of oral iron in the treatment of preoperative anaemia.

In contrast with the findings of the Cochrane review and the PREVENTT trial, a meta-analysis of patient blood management programme (PBM) studies, many of which include preoperative iron treatment as a component, found that there was a reduction in exposure to red cell transfusions. Although, the meta-analysis also found the implementation of PBM was not associated with a reduction on in-hospital mortality or 30-day mortality, there was no additive benefit from multiple interventions and no trial showed that PBM were cost-effective. Not included in this meta-analysis were recently published studies on the implementation of preoperative anaemia screening clinics in adults in elective colorectal surgery and major surgery which demonstrated reductions in red cell transfusions, length of stay, and net costs in patients with IDA who were treated with preoperative intravenous iron. Similarly, a large study from Western Australia reported significant reductions in cost associated with the use of blood products, and improved patient outcomes, after implementation of a PBM.

Studies investigating the impact of increasing preoperative Hb on perioperative outcomes in children are primarily focused on blood loss and blood transfusion rates in surgery in which significant bleeding and frequent blood transfusion are anticipated and most of the children in these studies received preoperative erythopoeitin. The impact of preoperative oral iron as a stand-alone intervention to increases preoperative Hb are limited to 2 studies. A single retrospective study has reported on the impact of the introduction of preoperative oral iron without erythropoeitin (EPO) in children undergoing spinal surgery. They found a significant difference in intraoperative transfusion rates in patients who received a longer duration of preoperative oral iron therapy. The major limitation of the study was a lack of preintervention Hb, precluding the ability to assess the effect of iron supplementation on delta Hb. A subsequent study reviewing the impact of preoperative oral iron in paediatric cardiac patients found that iron supplementation resulted in an increase in preoperative Hb levels which was associated with reduced red blood cell transfusion volumes.

Given the high incidence of preoperative anaemia in children having surgery in South Africa in the public sector and its association with poorer postoperative outcomes, it is important to assess the feasibility of a pragmatic intervention to treat preoperative anaemia in the context of a resource-constrained setting. Although intravenous iron in combination with EPO may be more effective and have fewer side effects, oral iron is relatively inexpensive and widely available in South Africa. Regular deworming may also play an important role in the treatment of preoperative anaemia and has been shown to be an effective intervention to increase baseline Hb in school age children from low- and middle- income countries. We hypothesise that the implementation of preoperative anaemia screening and treatment of anaemic patients with a minimum of 6 weeks supplementation with oral iron will have a clinically significant effect on increasing the Hb in patients with preoperative IDA.

STUDY OBJECTIVE To evaluate the efficacy of oral iron supplementation in children diagnosed with preoperative IDA undergoing noncardiac surgery.

STUDY DESIGN Pre and post- South African multi-centre interventional study of oral iron supplementation to treat IDA in paediatric patients (age >6 months and <16 years) admitted to participating hospitals undergoing elective non-cardiac surgery. The intention is to present a representative sample of paediatric surgical patients with preoperative anaemia. This study will run from January 2023 until July 2023.

ETHICS APPROVAL Ethics approval will be in place at each hospital site prior to recruitment of patients. Informed consent, and assent where appropriate, must be obtained for each participant enrolled in the study.

IMPORTANCE OF STUDY Preoperative anaemia is associated with significant morbidity and mortality. The information gained from this study will contribute to a greater understanding of the incidence of preoperative IDA in children in South Africa and give insight into the feasibility and efficacy of oral iron supplementation to treat preoperative IDA.

Being tested
Ferrous gluconate syrup or ferrous fumarate/folic acid tablets
Keywords
SAPSOS2
Medical subject headings
Anemia, Anemia, Iron-Deficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ferrous gluconate syrup or ferrous fumarate/folic acid tabletsDietary supplement

    Oral iron supplementation dosed based on body weight

Study groups in NCT05681871
Study groupRoleWhat they receive
Iron-deficiency anaemiaExperimentalParticipants will receive oral iron supplementation for a minimum of 4 weeks prior to surgery
Receives: Dietary Supplement: Ferrous gluconate syrup or ferrous fumarate/folic acid tablets

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Delta Haemoglobin = Change in haemoglobin pre- and post- oral iron supplementation

    g/dL

    Measured: 4-12 weeks

Secondary outcomes (1)
  1. Incidence of iron-deficiency anaemia

    Incidence of iron-deficiency anaemia

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jan 2023
  2. Study start9 Feb 2023
  3. Primary completion31 May 2025
  4. Study completion31 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Prospective interventional quasi-experimental pre-post study South African multi-centre
Masking
None (open label)
Enrolment
755 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05681871
Sponsor's protocol ID
N20221001
Acronym
SAPSOS2
Status last verified
Sep 2025
First submitted
3 Jan 2023
Last updated
18 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data sharing agreement has been finalised between the University of Cape Town and Professor Susan Goobie and Dr. Steven Staffa at Boston Children's Hospital. Purpose of this agreement is for statistical analysis and manuscript development. All shared data will undergo de-identification. Shared data includes eligibility, consent, reasons for exclusion, and de-identified record IDs, patient demographics, comorbidities, deworming status, planned date of surgery, hemocue results, pre-intervention formal Hb, MCV, reticulocyte count, CRP, ferritin levels, TSAT, information regarding medication compliance and any experienced side-effects, date of repeat Hb and post-intervention formal Hb, and serious adverse events.

Publications

  • Meyer HM, Torborg A, Biccard B, Kluyts H, Louw VJ, Cox S, Peer S, Arnold M, Cilliers C, Patel S, Benjamin Y, Solwa A, Smuts L, Parak A, Gerber C, Staffa SJ, Goobie SM. South African Paediatric Surgical Outcomes Study-2 (SAPSOS-2): a prospective multi-centre pre-post study evaluating haemoglobin response to oral iron for iron-deficiency anaemia in children undergoing elective noncardiac surgery. Br J Anaesth. 2026 Jul 1:S0007-0912(26)00397-1. doi: 10.1016/j.bja.2026.06.001. Online ahead of print.

    PubMed 42386436

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Ferrous gluconate syrup or ferrous fumarate/folic acid tablets in people with Paediatric Surgery and Anaemia, run by University of Cape Town at 2 sites in South Africa.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Delta Haemoglobin = Change in haemoglobin pre- and post- oral iron supplementation (time frame: 4-12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05681871, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in